Imatinib (Gleevec, Veenat, Imatib): — A Guide for Patients

Your team will arrange a full blood count, liver function tests, and kidney function tests before you start, then regularly through treatment. The blood count tracks your white cells and platelets, which imatinib can lower. Liver function tests are checked because imatinib can occasionally affect the liver, and most changes are caught early and managed by adjusting the dose. The frequency of testing usually reduces once your results are stable, but your team will set the schedule for you.

Veenat, made by Natco Pharma, and Imatib, made by Cipla, are Indian generic versions of imatinib. Both contain the same active ingredient at the same dose. Generics go through a regulatory process to establish that they behave the same way in the body as the originator drug. Indian oncologists have extensive experience with these generics and routinely prescribe them. If you have a specific concern about your prescription, raise it with your treating oncologist.

Take the missed dose as soon as you remember on the same day. If it is already the next day, skip the missed dose and continue with your usual schedule. Do not double up to make up for a missed dose. Missing a single dose occasionally is unlikely to affect your overall response, but missing doses regularly can reduce how well imatinib works. If you are finding it hard to remember, talk to your pharmacist or nurse — a phone reminder or a pill organiser is often all it takes.

Imatinib is broken down by the liver using an enzyme called CYP3A4. Medicines that affect this enzyme — including some antibiotics, antifungals, and anticonvulsants — can raise or lower the amount of imatinib in your blood. Grapefruit and grapefruit juice can also increase imatinib levels and should be avoided. Tell your team before taking any new medicine, including supplements and herbal remedies, because some widely used products can interact. Your pharmacist can check interactions.

For CML, treatment is usually long-term — often years. Stopping early without guidance from your oncologist significantly increases the chance of the disease returning. Some patients who achieve a very deep molecular response and sustain it for a prolonged period may be eligible to attempt treatment-free remission under close monitoring. This is a structured process, not something to try independently. Your oncologist will tell you if and when this becomes a realistic discussion for your situation.

In CML, a molecular response is measured by a blood test called a PCR test that detects the BCR-ABL gene at very low levels. Your team uses this test to track how well the treatment is working. The deeper the response, the fewer CML cells remain in your blood. European LeukemiaNet guidelines set response milestones at three, six, and twelve months after starting treatment. Missing a milestone does not automatically mean treatment has failed — it prompts a closer look and possibly a change in management.